Therapeutic-Specific Areas

Lundbeck to Acquire Alder BioPharmaceuticals in Deal Worth Up to $1.95 Billion

September 16, 2019

The acquisition will enhance Lundbeck’s brain disease therapy portfolio as well as its antibody process and development capabilities.

Sanofi, Abbott Partner to Advance Diabetes Management

September 16, 2019

The companies aim to integrate glucose sensing with insulin delivery technologies to help change the way diabetes is managed.

Passage Bio Establishes New Gene Therapy Development Program for Nerve Disorder

September 11, 2019

Passage Bio has licensed a sixth gene therapy development program under its partnership with the University of Pennsylvania for the clinical development of a potential treatment for a nerve disorder.

FDA Approves New Indication for Boehringer Ingelheim’s Lung Disease Drug

September 11, 2019

The agency has approved Boehringer Ingelheim’s Ofev (nintedanib), its lung disease drug, for the treatment of patients with systemic sclerosis associated with lung disease.

Xeris Pharmaceuticals Gets FDA Nod for Liquid Glucagon

September 11, 2019

Xeris Pharmaceuticals has received FDA approval for GVOKE (glucagon), a liquid glucagon for treating hypoglycemia.

Global Hemophilia A and B Market Projected to Reach $9.3 Billion by 2028

September 06, 2019

A new report by GlobalData projects 2.9% growth by 2028 for the hemophilia A and B market across the eight major world markets.

AbbVie Halts Development of Investigational Lung Cancer ADC

September 04, 2019

In a Phase III trial for advanced small-cell lung cancer, the investigational antibody drug conjugate, Rova-T (rovalpituzumab tesirine), did not demonstrate a survival benefit for patients taking it.

Janssen Gets FDA Breakthrough Therapy Designation for RSV Vaccine

September 04, 2019

The company has received breakthrough therapy designation for its prophylactic respiratory syncytial virus vaccine candidate for treating adults aged 60 years or older.

Vertex to Acquire Semma Therapeutics in $950-Million Deal

September 04, 2019

Vertex will use the acquisition to develop cell-based treatments for type 1 diabetes.

FDA Grants Xtandi Application Priority Review for Additional Indication in Prostate Cancer

August 26, 2019

The supplemental new drug application seeks to add an indication for men with prostate cancer that has spread but is sensitive to hormone therapy.